04 Jan '23
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
Highlights Expected Special Cash Dividend of Approximately $70 Million , and Upside of CVR and Ownership of Combined Company CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2023-- Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment
Displaying 11 - 12 of 12